

Interesting Images

Not peer-reviewed version

---

# When Infection Lurks Behind Malignancy: A Unique Case of Primary Bone Lymphoma Mimicking Infectious Process in the Spine

---

[Ayoub Jaafari](#) \* , [Ornella Rizzo](#) , Sohaïb Mansour , Anas Chbabou , Anne-Laure Trepant , Rachid Attou , Céline Mathey

Posted Date: 24 June 2024

doi: 10.20944/preprints202406.1574.v1

Keywords: Primary bone lymphoma; Diffuse large B-cell lymphoma; Spondylodiscitis; 18F-FDG-PET/CT; MRI.



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Disclaimer/Publisher's Note: The statements, opinions, and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions, or products referred to in the content.

## Interesting Images

# When Infection Lurks behind Malignancy: A Unique Case of Primary Bone Lymphoma Mimicking Infectious Process in the Spine

Ayoub Jaafari <sup>1,\*</sup>, Ornella Rizzo <sup>2</sup>, Sohaïb Mansour <sup>3</sup>, Chbabou Anas <sup>4</sup>, Anne-Laure Trepant <sup>5</sup>, Rachid Attou <sup>6</sup> and Celine Mathey <sup>1</sup>

<sup>1</sup> Department of Nuclear Medicine, H.U.B Erasme Hospital, Brussels, Belgium, Ayoub.jaafari@ulb.be; celine.mathey@hubruxelles.be;

<sup>2</sup> Department of Haematology, H.U.B Bordet Hospital, Brussels, Belgium, Ornella.rizzo@hubruxelles.be;

<sup>3</sup> Department of Internal Medicine, C.H.U Brugmann, Brussels, Belgium, sohaib.mansour@chu-brugmann.be;

<sup>4</sup> Department of Radiology, C.H.U Saint-Pierre, Brussels, Belgium, anas.chbabou@ulb.be;


<sup>5</sup> Department of Anatomopathological, H.U.B Erasme Hospital, Brussel, Belgium, anne-laure.trepant@hubruxelles.be;

<sup>6</sup> Department of Intensive Care Unit, C.H.U Brugmann, Brussels, Belgium, rachid.attou@chu-brugmann.be;

\* Correspondence: ayoub.jaafari@ulb.be

**Abstract:** Primary bone lymphoma of the spine (PBL) is a rare entity and the most shared type of non-Hodgkin lymphoma (LNH) appearing in bone lesions deprived of nodal or extra-nodal involvement and accounting for approximately 2% of all lymphomas. Most PBL are diffuse large B-cell lymphomas (DLBCL) and commonly involve the appendicular skeleton. Due to its atypical location and non-specific clinical imaging features mimicking certain neoplastic or infectious processes, this pathology may be misdiagnosed, thus complicating and delaying diagnosis. Our case reports a patient in her sixties who had been suffering from chronic low back pain for a year, and had gradually started to develop cruralgia and fever. She underwent a blood sample, magnetic resonance imaging (MRI), and positron emission tomography (<sup>18</sup>F-FDG-PET/CT) which revealed significant inflammatory syndrome, a pattern of spondylodiscitis at the L3-L4 level associated with morphological and metabolic invasion extending posteriorly, raising suspicion of epiduritis. No other lesions were found on the rest of the body. Neurosurgical management was performed and a biopsy was made. Histological results showed aggressive and diffuse large B-cell lymphoma, suggesting a diagnosis of PBL. This case highlights the first case of spondylodiscitis mimicking PBL in the lumbar spine, the intricacies of the diagnostic work-up, and the complexity of discriminating with an infectious process in the spine, as both have a similar, non-specific clinical presentation with different prognosis and therapeutic management.


**Keywords:** primary bone lymphoma; diffuse large B-cell lymphoma; spondylodiscitis; <sup>18</sup>F-FDG-PET/CT; MRI




**Figure 1.**  $^{18}\text{F}$ -FDG-PET/CT of the patient: (A) Maximum Intensity Projection (MIP) of the entire body, (B) Maximum Intensity Projection (MIP), (C) merged images, and (D) CT-images of the lumbosacral area. A 62-year-old patient without a significant pre-existing medical history presented with chronic mechanical low back pain since the summer of 2022. She had previously undergone a magnetic resonance imaging (MRI) of the spine in favor of a narrow lumbar canal (Figure 2A), for which she was treated with multiple analgesics and infiltrations until the summer of 2023, with an improvement of the symptomatology. However, since October 2023, her symptoms have worsened. The patient presented no nocturnal sweating, was pyretic (maximum of  $38.5^\circ\text{C}$ ), and slightly decreased her appetite. On clinical examination, discrete paresis of the left quadriceps was observed. Bearing in mind the patient's condition at the time of consultation, she was quickly admitted to the hospital where further exams were carried out. Laboratory tests showed a small elevated serum white-blood cells ( $12.2 \times 10^3/\mu\text{L}$ ), predominantly neutrophilic ( $8.4 \times 10^3/\mu\text{L}$ ), and a concentration of C-reactive protein (175mg/dL). The other biological tests came back unremarkable. She underwent an MRI, which revealed a very dubious image showing remodeling of the L3 vertebra (bone marrow replacement) and of the intervertebral disc between L3 and L4, suggesting suspected spondylitis vs spondylodiscitis (Figure 2B). Broad-spectrum antibiotics were subsequently started. In view of her symptoms and recent weight loss, she also underwent an  $^{18}\text{F}$ -FDG-PET/CT showing a higher uptake in this widespread invasion at the L3 level with an infectious appearance and more aggressive metabolic extension anteriorly and posteriorly, associated with epiduritis. No other lesions were found on the rest of the body (Figure 2). Neurosurgical management (decompression and L3-laminectomy) was performed and samples were taken. Histological results showed aggressive and diffuse large-cell B lymphoma (DLBCL), stage IV (Ann-Harbor classification). Immuno-histochemical were as follows: CD20+, PAX5+, CD3/CD5 -, BCL6+, MUM1-, Cycline D1-, BCL2+, cMyc-, Ki-67 80%, consistent with DLBCL, non-germinal center B-cell like (Figure 3). A diagnosis of primary bone lymphoma of the lumbar spine was made. Chemotherapy (R-CHOP and methotrexate) was administered to the patient with clinical, morphologic, and metabolic improvement after 4 cycles (Figures 4 and 5). Firstly described by Oberling et al. in 1928, primary bone lymphoma in the spine (PBL) remains a scarce entity and the utmost shared type of non-Hodgkin lymphoma (LNH) appearing in bone lesions deprived of nodal or extra-nodal involvement, accounting for approximately 3-7% amongst primary bone tumors and 2% of all lymphomas [1]. The predominant diagnosis age of patients is over 30, with a median of 45, and more predominant in men than women, with a ratio of 1.5:1[1]. Most PBL are diffuse large B-cell lymphomas (DLBCL) and commonly involve the appendicular skeleton [2]. Because infection and malignant tumors have certain characteristics in common that complicate and delay diagnosis, PBL can be underdiagnosed, particularly with tumors

invading the spine/spinal cord or nerves such as sarcoma, plasmacytoma, or infectious processes such as osteomyelitis or spondylodiscitis. Here, we present the first unique case of an atypical cruralgia in terms of tumor location and clinical presentation, the <sup>18</sup>F-FDG-PET/CT and MRI findings, and therapeutic management. The non-specific clinical manifestations and inconclusive laboratory tests of PBL can be quite frustrating, and heterogeneous in its presentation, frequently resulting in a delayed diagnosis [2]. The most common symptom is localized bone pain, predominantly in the appendicular skeleton, which is difficult to relieve with rest and may progressively worsen over time [3]. Patients may sometimes experience 'B' symptoms including fever, night sweats, and unwanted weight loss. These symptoms occur in a minority of patients and are not as frequent in PBL as in systemic lymphoma [4]. In our case, the patient reported a "red flag" sign (unwanted weight loss) associated with cruralgia and inflammatory syndrome, suggesting an infectious process on the first hypothesis. PBL can arise in any part of the musculoskeletal system and can occasionally manifest as soft tissue masses that can be misidentified for infection or malignancy [5,6]. Moreover, symptoms of spinal cord compression are reported in approximately less than 20% [5,6]. According to the literature, this paper reported the first case of PBL mimicking an isolated infectious process in the spine. As far, few case reports of PBL infiltrated spinal nerve roots and ganglia have been described but nothing related to our case [7,8]. Since infections and malignant tumors share characteristics that complicate the differential diagnosis and delay appropriate treatment, multiple modalities including clinical examination, laboratory sampling, biopsy samples, and imaging techniques are required. In morphological imaging, magnetic resonance imaging (MRI) has been proven to be significant in the staging of PBL [9]. However, MRI cannot discriminate non-viable from viable malignancies as shown in our patient (Figure 2B), and therefore cannot be convenient where bone infections are present. In contrast, MRI is currently the method of choice for diagnosing spondylodiscitis, demonstrating a hyposignal in T1 and a hypersignal in T2 phase (Figure 2B) [10]. It provides information on bone marrow, vertebral disks, and neural structures. In metabolic imaging, management with 2-[<sup>18</sup>F]-fluoro-2-deoxy-D-glucose (<sup>18</sup>F-FDG) positron emission tomography combined with computed tomography (PET/CT) is mainly used to identify high-uptake lesions. This hybrid imaging method provides information on metabolic characteristics and anatomical location. It has been approved for the staging and therapeutic follow-up of patients with Hodgkin's disease (HD) and NHL [11]. Study data with PBL also speculated that <sup>18</sup>F-FDG-PET/CT may provide significant information for management decisions [11,12]. In spondylodiscitis, some studies have suggested that <sup>18</sup>F-FDG-PET/CT is slightly more sensitive and accurate than MRI, particularly in the early stages, because the metabolism of the lesion appears much earlier than the morphological alterations on MRI [12,13]. Nevertheless, discrimination between malignant and infectious processes is sometimes challenging with <sup>18</sup>F-FDG-PET/CT. While maximum higher standardized uptake values (SUVmax) are associated with a greater probability of malignancy, no threshold for uptake allows us to distinguish both processes [14]. For example, a prospective study conducted by Skawran et al. evaluated 77 cancerous and inflammatory/infectious lesions in 24 patients using different <sup>18</sup>F-FDG-PET/CT parameters and showed no significant difference between infectious from malignant lesions using SUVmax [15]. In our case, the patient had no risk factors for spondylodiscitis (no recent spinal surgery, diabetes, pre-existing infection, iatrogenic or human immunosuppression, etc.), and the weight loss, fever, and cruralgia didn't appear until very late (1 year). It is possible that the various lumbar infiltrations carried out to relieve the pain served as an entry point for a bacterium that could have proliferated, giving rise to the initial suspicion of spondylodiscitis. FDG-uptake in the L3-lesion was very intense (SUVmax: 35) and correlated with a metabolic image of anterior and posterior "inflammatory cast" invading the spinal cord, suggesting an infectious origin as a first hypothesis but which was misdiagnosed in favor of an aggressive LDBCL. Clearly, in most cases, biopsy or pathology results are required to confirm the final diagnosis. More recently, interest in the <sup>18</sup>F-FDG-PET/MRI hybrid imaging has grown. This new modality combines the physiological information acquired by PET with the very high resolution of soft tissue and the contrast of MRI, reducing the number of examinations required for the patient and scanner-related irradiation (Figure 2C) [13]. In PBL, <sup>18</sup>F-FDG-PET/MRI has shown encouraging results in early studies and exposed similar sensitivity with <sup>18</sup>F-FDG-PET/CT [16]. In vertebral osteomyelitis, a prospective study conducted by Kouijzer et al. showed promising results as a complementary fusion-imaging technique with <sup>18</sup>F-FDG-PET/MRI [17]. Mainly speaking,


more studies are needed to fully demonstrate its benefit. In conclusion, our case illustrates the difficulty of discriminating between PBL and spondylodiscitis, as both have a similar, non-specific clinical and laboratory presentation, while morphological and metabolic findings may be similar to each other. For precise diagnosis, we recommend fully incorporating primary bone lymphoma as a differential diagnosis in patients presenting with an inflammatory syndrome associated with neurological defects and warning signs, and combining clinical diagnosis, laboratory tests, fusion imaging methods, and biopsies to avoid delaying appropriate treatment.



**Figure 2.** MRI (T1-T2 phases) undergone in July 2022 showed disc disease in posterior L2-L3 and especially L3-L4 (white arrow), discreetly reducing the diameter of the canal, with a relative secondary narrowing of the canal (A). The MRI carried out in December 2023 showed bone marrow replacement of almost the entire L3-vertebral body in both phases and the intervertebral disc between L3 and L4 (long white arrow), suggesting suspected spondylitis vs spondylodiscitis (Figure 2B). However, a neoplastic pathology could not be ruled out. A merged image of <sup>18</sup>F-FDG-PET and MRI showed aggressive widespread invasion at the L3 and doubtful at the L3-L4 level intervertebral disc, with an infectious appearance and metabolic extension anteriorly and posteriorly (head arrow), associated with epiduritis (C).



**Figure 3.** Biopsy of infiltrating lesion of the L3 vertebra showing aggressive DLBCL. Immunostaining of the lesion is positive for hematoxylin-eosin HE (A), CD20+ (B), KI-67 (C), and BCL2 (D). Because PBLs are often DLBCLs, according to the literature, the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) associated with methotrexate for preventing central nervous system (CNS) is the most current protocol therapy for patients with aggressive DLBCL [18]. Our patient underwent 4 cycles of chemotherapy with an improvement in her symptomatology and morphological and metabolical imaging (Figure 4).



**Figure 4.**  $^{18}\text{F}$ -FDG-PET/CT showing complete metabolic response/normalization at the L3 vertebra level and the L3-L4 intervertebral disc after decompression and particularly 4 cycles of chemotherapy (white arrows).

**Authors contributions:** “Conceptualization, A.J.; methodology, A.J, S.M.; software, A.J, A.C, C.M; formal analysis A.J, C.M, A.R.; investigation, A.J, S.M, R.A.; resources, O.R, A.T, C.M.; data curation, A.J, O.R, C.M, A.C, ; writing—original draft preparation, A.J; writing—review and editing, O.R, R.A, C.M; visualization, A.C, S.M; supervision, C.M. All authors have read and agreed to the published version of the manuscript.”.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** This study did not receive ethical review and approval due to the nature of the research (case report).

**Informed Consent Statement:** Written informed consent was obtained from the patient. The consent form was obtained on 01.03.2024.

**Data Availability Statement:** The data used and analyzed in this study are available from the corresponding author on reasonable request.

**Conflicts of Interest:** The authors declare no conflicts of interest.

## References

1. S. Bhagavathi and K. Fu, "Primary lymphoma of bone: a review," *Seminars in Diagnostic Pathology*, vol. 31, no. 1, pp. 48–52, 2014.
2. Mikhaeel NG. Primary Bone Lymphoma. *Clinical Oncology*. 2012 Jun;24(5):366–70.
3. Mika J, Schleicher I, Gerlach U, Adler CP, Uhl M, Knoeller SM. Primary bone lymphomas thought to be osteomyelitis urgently demand a rapid diagnosis in bone pathology. *Anticancer Res*. 2012;32(11):4905–4912.
4. Demircay E, Hornicek FJ, Mankin HJ, Degroot H. Malignant Lymphoma of Bone: A Review of 119 Patients. *Clinical Orthopaedics & Related Research*. 2013 Aug;471(8):2684–90.
5. Kanavos T, Birbas E, Papoudou-Bai A, Hatzimichael E, Kitsouli A, Karpathiou G, et al. Primary Bone Lymphoma: A Review of the Literature with Emphasis on Histopathology and Histogenesis. *Diseases* [Internet]. 2023 Mar 1 [cited 2023 Mar 9];11(1):42.
6. Wang SJ, Cao DL, Xu HW, Zhao WD, Hu T, Wu DS. Development of Primary Diffuse Large B-Cell Lymphoma Around an Internal Fixation Implant After Lumbar Fusion Surgery: A Case Report and Review of the Literature. *World Neurosurgery* [Internet]. 2020 May 1 [cited 2022 May 17]; 137:140–5.
7. Kim SK, Lee SH, Kim ES, Eoh W. Diffuse Large B-Cell Lymphoma Mimicking Schwannoma of Lumbar Spine. *Korean Journal of Spine*. 2016;13(2):71.
8. Tsai MC. Non-Hodgkin's B-cell lymphoma of a lumbar nerve root: A rare cause of lumbar radiculopathy. *Journal of Clinical Neuroscience*. 2013 Jul;20(7):1029–31.
9. Zhou H, Gao F, Bu B, Fu Z, Sun X, Huang C, et al. Primary bone lymphoma: A case report and review of the literature. *Oncology Letters* [Internet]. 2014 Jul 9;8(4):1551–6.
10. Herren C, Jung N, Pishnamaz M, Breuninger M, Siewe J, Sobottke R. Spondylodiscitis: Diagnosis and Treatment Options. *Deutsches Aerzteblatt Online* [Internet]. 2017.
11. Hutchings M, Barrington SF. PET/CT for Therapy Response Assessment in Lymphoma. *The Journal of Nuclear Medicine*. 2009 Apr 20;50(Suppl 1):21S30S.
12. Altini C, Lavelli V, Niccoli-Asabella A, Sardaro A, Branca A, Santo G, et al. Comparison of the Diagnostic Value of MRI and Whole Body 18F-FDG PET/CT in Diagnosis of Spondylodiscitis. *Journal of Clinical Medicine*. 2020 May 22;9(5):1581.
13. Behzadi AH, Raza SI, Carrino JA, Kosmas C, Gholamrezanezhad A, Basques K, et al. Applications of PET/CT and PET/MR Imaging in Primary Bone Malignancies. *PET clinics* [Internet]. 2018 Oct 1 [cited 2021 Aug 18];13(4):623–34.
14. Bleeker-Rovers CP, Vos FJ, Graaf WTA, Oyen WJG. Nuclear Medicine Imaging of Infection in Cancer Patients (With Emphasis on FDG-PET). *The Oncologist*. 2011 Jun 16;16(7):980–91.
15. Skawran S, Messerli M, Kotasidis F, Trinckauf J, Weyermann C, Kudura K, et al. Can Dynamic Whole-Body FDG PET Imaging Differentiate between Malignant and Inflammatory Lesions? *Life* [Internet]. 2022 sept;12(9):1350.
16. Rajan Rakheja, Hersh Chandarana, DeMello L, Jackson K, Geppert C, Faul D, et al. Correlation Between Standardized Uptake Value and Apparent Diffusion Coefficient of Neoplastic Lesions Evaluated With Whole-Body Simultaneous Hybrid PET/MRI. *American Journal of Roentgenology*. 2013 Oct 22;201(5):1115–9.

17. Kouijzer IJE, Scheper H, de Rooy JWJ, Bloem JL, Janssen MJR, van den Hoven L, et al. The diagnostic value of 18F-FDG-PET/CT and MRI in suspected vertebral osteomyelitis – a prospective study. *European Journal of Nuclear Medicine and Molecular Imaging*. 2017 Dec 19;45(5):798–805.
18. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB de O, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. *Leukemia*. 2022 Jun 22;36(7):1720–48.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.